Cellectar Biosciences, Inc. (CLRB)

$3.6806

+0.18 (+5.16%)
Rating:
Recommendation:
Neutral
Symbol CLRB
Price $3.6806
Beta 1.246
Volume Avg. 0.02M
Market Cap 22.489M
Shares () -
52 Week Range 3.4-10.3
1y Target Est -
DCF Unlevered CLRB DCF ->
DCF Levered CLRB LDCF ->
ROE -85.06% Strong Sell
ROA -97.76% Strong Sell
Operating Margin -
Debt / Equity 28.22% Neutral
P/E -
P/B 1.11 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CLRB news


Mr. James Caruso
Healthcare
Biotechnology
NASDAQ Capital Market

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.